Context Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Context Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-174,065	Closed	-$1.72M	–	706
2021 Q4	$1.72M	Hold	174,065	–	–	0.13%	220
2021 Q3	$1.73M	Hold	174,065	–	–	0.18%	156
2021 Q2	$1.69M	Hold	174,065	–	–	0.16%	155
2021 Q1	$1.68M	Buy	+174,065	New	+$1.77M	0.16%	155

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Context Capital Management's TLSI Position: Q1 2022 in Review

Context Capital Management sold out of TriSalus Life Sciences (TLSI) in Q1 2022, closing a stake of 174,065 shares — an estimated $1.72M sold.

Context Capital Management first reported a position in TLSI in Q1 2021 and held it in 4 quarters. The position peaked at $1.73M in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q1 2022.

Context Capital Management reported no remaining TriSalus Life Sciences position as of Q1 2022 after selling out during the quarter.
Context Capital Management sold 174,065 TriSalus Life Sciences shares in Q1 2022, an estimated $1.72M.
Context Capital Management first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 4 quarters.
Context Capital Management's TriSalus Life Sciences position peaked at $1.73M in Q3 2021.
68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2022.

Based on Context Capital Management's 13F filing for Q1 2022, filed 9 May 2022.